Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Rallybio's Business Segments
Rallybio's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reporting
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reporting100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reporting | $ 0 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Collaboration and License Revenue100%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration and License Revenue | $ 0 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Rallybio
Rallybio Corporation is a US-based biopharmaceutical company that is focused on the development of novel treatments for rare and serious diseases. Founded in 2018, the company has quickly become one of the leading players in the biotech industry, thanks to its innovative drug discovery platform and strong team of scientists, researchers, and business professionals.
The mission of Rallybio Corporation is to discover and develop life-changing therapies that can address unmet medical needs in patients with rare diseases. The company is dedicated to advancing the science of drug development and pushing the boundaries of what is possible in the field of biotechnology.
One of the key strengths of Rallybio Corporation is its deep expertise in the biology of rare diseases. The company's team of experts includes some of the most renowned scientists and researchers in the field, who have a wealth of experience in the discovery and development of new treatments for rare and orphan diseases.
Rallybio Corporation is currently focusing on the development of a pipeline of innovative drug candidates that have the potential to transform the lives of patients with rare and serious illnesses. The company's lead program is a monoclonal antibody therapy designed to treat patients with severe hemophilia A.
In addition to its lead program, Rallybio Corporation has a number of other drug candidates in the pipeline, including treatments for rare genetic disorders such as lysosomal storage diseases, immune-mediated diseases, and other serious conditions.
One of the key factors that sets Rallybio Corporation apart from its competitors is its strategic approach to drug development. The company is focused on developing targeted therapies that address the specific molecular mechanisms that underlie rare diseases, which enables them to deliver highly effective and precise treatments that have minimal side effects.
Overall, Rallybio Corporation is an exciting and dynamic biotech company that is making significant strides in the discovery and development of innovative drug therapies for rare and serious diseases. With its strong team of experts and cutting-edge technology platform, the company is well-positioned to become a major player in the biotech industry over the coming years.
The mission of Rallybio Corporation is to discover and develop life-changing therapies that can address unmet medical needs in patients with rare diseases. The company is dedicated to advancing the science of drug development and pushing the boundaries of what is possible in the field of biotechnology.
One of the key strengths of Rallybio Corporation is its deep expertise in the biology of rare diseases. The company's team of experts includes some of the most renowned scientists and researchers in the field, who have a wealth of experience in the discovery and development of new treatments for rare and orphan diseases.
Rallybio Corporation is currently focusing on the development of a pipeline of innovative drug candidates that have the potential to transform the lives of patients with rare and serious illnesses. The company's lead program is a monoclonal antibody therapy designed to treat patients with severe hemophilia A.
In addition to its lead program, Rallybio Corporation has a number of other drug candidates in the pipeline, including treatments for rare genetic disorders such as lysosomal storage diseases, immune-mediated diseases, and other serious conditions.
One of the key factors that sets Rallybio Corporation apart from its competitors is its strategic approach to drug development. The company is focused on developing targeted therapies that address the specific molecular mechanisms that underlie rare diseases, which enables them to deliver highly effective and precise treatments that have minimal side effects.
Overall, Rallybio Corporation is an exciting and dynamic biotech company that is making significant strides in the discovery and development of innovative drug therapies for rare and serious diseases. With its strong team of experts and cutting-edge technology platform, the company is well-positioned to become a major player in the biotech industry over the coming years.
Rallybio Corporation is a biotechnology company that is dedicated to the development of advanced medicines aimed at addressing the unique challenges associated with rare diseases. The company’s commitment to innovation is reflected in its well-defined segments, diverse product portfolio, and comprehensive range of services tailored to meet the needs of patients and healthcare professionals.
Segments:
1. Research and Development (R&D):
The R&D segment is a cornerstone of Rallybio Corporation’s operations. It encompasses a systematic and rigorous approach to discovering and developing innovative therapeutic solutions for rare diseases. The company invests significant resources into identifying rare disease targets and deploying sophisticated methodologies, including cutting-edge biotechnologies and scientific research. This segment not only focuses on drug discovery but also emphasizes preclinical and clinical development, ensuring that novel therapies undergo thorough testing for efficacy, safety, and tolerability.
2. Commercialization:
The Commercial segment is pivotal in bringing Rallybio’s innovative products to market. This includes establishing partnerships with other biotechnology and pharmaceutical companies to leverage complementary strengths and facilitate market entry. The company actively seeks to broaden access to its treatments through strategic collaborations, licensing agreements, and alliances. This segment is integral to developing a commercial pathway that ensures patients globally can access critical therapies designed for their specific conditions.
Products:
Rallybio Corporation’s product portfolio consists of several promising drug candidates, each targeting a distinct rare disease:
1. RLYB211:
This drug is under development to address pyruvate kinase deficiency (PKD), which is a genetic condition that leads to chronic hemolytic anemia. By targeting the underlying mechanisms of PKD, RLYB211 aims to enhance the red blood cells’ ability to transport oxygen effectively, improving overall patient health and quality of life.
2. RLYB212:
RLYB212 is focused on the treatment of Immune Thrombocytopenic Purpura (ITP), a disorder characterized by an abnormally low platelet count, leading to increased risk of bleeding. This therapeutic candidate is being developed to modulate the immune response and promote an increase in platelet production, thus mitigating the symptoms associated with ITP.
3. RLYB340:
Designed for patients with Alagille syndrome (ALGS), RLYB340 addresses a complex genetic disorder impacting multiple systems, including the liver, heart, and kidneys. This therapeutic aims to provide a targeted approach to manage the diverse symptoms and complications associated with ALGS, thereby enhancing patient outcomes and minimizing the progression of the disease.
4. RLYB898:
RLYB898 is being developed for Phelan-McDermid syndrome (PMS), a rare genetic disorder that affects cognitive and developmental processes. The goal of this drug candidate is to affect neurodevelopment positively, improving cognitive function and overall quality of life for patients and their families coping with this condition.
Services:
In complement to its therapeutic developments, Rallybio Corporation offers a suite of services that support patients, healthcare providers, and the broader healthcare ecosystem:
1. Clinical Trials:
Rallybio actively conducts clinical trials to explore the safety, efficacy, and optimal dosing of its drug candidates. These trials are critical in validating the therapeutic potential and are conducted in compliance with regulatory standards to ensure participant safety and data integrity.
2. Patient Support Programs:
Understanding the complexities associated with rare disease treatment, Rallybio provides robust patient support programs. These initiatives aim to assist patients and caregivers in navigating their treatment pathways, offering resources, guidance, and emotional support throughout the process.
3. Medical Education:
Rallybio Corporation takes an active role in medical education, implementing programs designed to enhance the understanding of rare diseases among healthcare professionals. By fostering education and awareness, Rallybio aims to improve diagnosis, treatment, and care standards for affected individuals.
4. Advocacy Support:
The company collaborates with patient advocacy organizations to amplify the voices of patients and families impacted by rare diseases. By supporting these advocacy efforts, Rallybio contributes to raising awareness, influencing relevant policies, and promoting research initiatives that may benefit the rare disease community.
In summary, Rallybio Corporation stands at the forefront of biotechnology innovation with a dedicated focus on rare diseases. Through its comprehensive segments, targeted product pipeline, and supportive services, the company is committed to transforming the treatment landscape for patients facing the challenges posed by rare conditions.
Segments:
1. Research and Development (R&D):
The R&D segment is a cornerstone of Rallybio Corporation’s operations. It encompasses a systematic and rigorous approach to discovering and developing innovative therapeutic solutions for rare diseases. The company invests significant resources into identifying rare disease targets and deploying sophisticated methodologies, including cutting-edge biotechnologies and scientific research. This segment not only focuses on drug discovery but also emphasizes preclinical and clinical development, ensuring that novel therapies undergo thorough testing for efficacy, safety, and tolerability.
2. Commercialization:
The Commercial segment is pivotal in bringing Rallybio’s innovative products to market. This includes establishing partnerships with other biotechnology and pharmaceutical companies to leverage complementary strengths and facilitate market entry. The company actively seeks to broaden access to its treatments through strategic collaborations, licensing agreements, and alliances. This segment is integral to developing a commercial pathway that ensures patients globally can access critical therapies designed for their specific conditions.
Products:
Rallybio Corporation’s product portfolio consists of several promising drug candidates, each targeting a distinct rare disease:
1. RLYB211:
This drug is under development to address pyruvate kinase deficiency (PKD), which is a genetic condition that leads to chronic hemolytic anemia. By targeting the underlying mechanisms of PKD, RLYB211 aims to enhance the red blood cells’ ability to transport oxygen effectively, improving overall patient health and quality of life.
2. RLYB212:
RLYB212 is focused on the treatment of Immune Thrombocytopenic Purpura (ITP), a disorder characterized by an abnormally low platelet count, leading to increased risk of bleeding. This therapeutic candidate is being developed to modulate the immune response and promote an increase in platelet production, thus mitigating the symptoms associated with ITP.
3. RLYB340:
Designed for patients with Alagille syndrome (ALGS), RLYB340 addresses a complex genetic disorder impacting multiple systems, including the liver, heart, and kidneys. This therapeutic aims to provide a targeted approach to manage the diverse symptoms and complications associated with ALGS, thereby enhancing patient outcomes and minimizing the progression of the disease.
4. RLYB898:
RLYB898 is being developed for Phelan-McDermid syndrome (PMS), a rare genetic disorder that affects cognitive and developmental processes. The goal of this drug candidate is to affect neurodevelopment positively, improving cognitive function and overall quality of life for patients and their families coping with this condition.
Services:
In complement to its therapeutic developments, Rallybio Corporation offers a suite of services that support patients, healthcare providers, and the broader healthcare ecosystem:
1. Clinical Trials:
Rallybio actively conducts clinical trials to explore the safety, efficacy, and optimal dosing of its drug candidates. These trials are critical in validating the therapeutic potential and are conducted in compliance with regulatory standards to ensure participant safety and data integrity.
2. Patient Support Programs:
Understanding the complexities associated with rare disease treatment, Rallybio provides robust patient support programs. These initiatives aim to assist patients and caregivers in navigating their treatment pathways, offering resources, guidance, and emotional support throughout the process.
3. Medical Education:
Rallybio Corporation takes an active role in medical education, implementing programs designed to enhance the understanding of rare diseases among healthcare professionals. By fostering education and awareness, Rallybio aims to improve diagnosis, treatment, and care standards for affected individuals.
4. Advocacy Support:
The company collaborates with patient advocacy organizations to amplify the voices of patients and families impacted by rare diseases. By supporting these advocacy efforts, Rallybio contributes to raising awareness, influencing relevant policies, and promoting research initiatives that may benefit the rare disease community.
In summary, Rallybio Corporation stands at the forefront of biotechnology innovation with a dedicated focus on rare diseases. Through its comprehensive segments, targeted product pipeline, and supportive services, the company is committed to transforming the treatment landscape for patients facing the challenges posed by rare conditions.